相关实验视频

Updated: Jul 1, 2025

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus

Published on: July 31, 2021

围产期结局和怀孕期间的Sinopharm BBIBP-CorV疫苗接种

Donya Hatami¹, Abbas Habibelahi², Nasrin Changizi³

¹Preventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Department of Community and Family Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

BMC pregnancy and childbirth

|March 12, 2024

概括

使用Sinopharm疫苗的孕妇接种COVID-19疫苗显示,早产,极早产和死产的风险降低. 然而,第一季度疫苗接种与早产风险更高有关.

科学领域:

产科和妇科产科和妇科
传染性疾病传染性疾病
公共卫生公共卫生

背景情况:

COVID-19不成比例地影响孕妇,增加了严重的结果.
接种SARS-CoV-2疫苗是作为一种减轻怀孕期间严重COVID-19的策略而出现的.
从2021年8月开始,伊朗的孕妇接种了Sinopharm疫苗.

研究的目的:

调查针对SARS-CoV-2接种疫苗的孕妇中不良周产期结局的发生率.
在伊朗怀孕期间评估Sinopharm疫苗的安全性和有效性.

主要方法:

伊朗德黑兰129,488名单胎婴儿的回顾性队列研究 (2021年3月至2022年3月).
数据来源于伊朗孕产妇和新生儿 (IMaN) 网络和孕产妇疫苗注册表.
用多重逻辑回归来分析围产期结果,包括早产,低出生体重,死产和先天异常.

主要成果:

13.5%的分娩 (17,485) 来自接种疫苗的母亲 (Sinopharm).
接种疫苗显著减少了早产 (OR=0.91),极早产 (OR=0.55),以及死产 (OR=0.60).
第一季度接种疫苗与早产风险增加相关 (OR=1.27);其他结果的风险没有增加.

结论:

在第二个和第三个三个月内接种Sinopharm疫苗没有显示出任何不良妊娠结果.
接种疫苗和未接种疫苗的孕妇的整体不良妊娠结果较低.
第一季度接种疫苗与早产风险增加有关.

关键词:

BIBP的COVID-19疫苗是如何使用的在 COVID-19 疫情中,关于COVID-19疫苗的使用情况孕产妇的COVID-19感染情况围产期结局的结果疫苗的安全性疫苗的安全性

更多相关视频

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C

Published on: March 25, 2016

Probiotic Studies in Neonatal Mice Using Gavage

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

相关概念视频

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...